| Treatment of complications associated with systemic sclerosis. | |
| | |
MedLine Citation:
|
PMID: 18238768 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: Current and emerging drug therapy options for patients suffering from the complications of systemic sclerosis are presented. SUMMARY: Systemic sclerosis is a devastating and rare, chronic, autoimmune disease and is characterized by various disease complications due to skin thickening, vascular damage, and inflammation affecting numerous organs. There are two major subtypes of systemic sclerosis: limited cutaneous scleroderma and diffuse cutaneous scleroderma. Patients suffer from Raynaud's phenomenon, skin changes, musculoskeletal changes, gastrointestinal complications, pulmonary complications, scleroderma renal crisis, and dryness of the eyes and mouth. Currently, there is no cure for systemic sclerosis, but research is focusing on decreasing the progression and symptoms of this disease. Raynaud's phenomenon is the temporary vasoconstriction of the small vessels of the fingers, toes, tip of the nose, and earlobes. Skin thickening is the cardinal symptom of systemic sclerosis, with as many as 50% of patients developing digital ulcers. Care of these ulcers is crucial in the prevention of osteomyelitis and other infections. Malabsorption syndrome may also occur in patients, many of whom will eventually require parenteral nutrition to maintain their caloric needs. Pulmonary interstitial fibrosis and pulmonary arterial hypertension are additional serious complications of systemic sclerosis. The use of prostacyclin analogues, phosphodiesterase inhibitors, calcium-channel blockers, cyclophosphamide, bosentan, and other agents has been investigated in patients suffering from the complications of systemic sclerosis. CONCLUSION: Systemic sclerosis is characterized by various circulatory, dermatological, gastrointestinal, musculoskeletal, pulmonary, and renal complications. Although there is no cure for systemic sclerosis, management of its associated complications can help improve patients' quality of life. |
| | |
Authors:
|
Stacie C Moore; Evelyn R Hermes Desantis |
Related Documents
:
|
15192318 - Magical ideation -- defense mechanism or neuropathology? a study with multiple sclerosi... 10805338 - Evidence for infection with chlamydia pneumoniae in a subgroup of patients with multipl... 15711498 - Natalizumab (tysabri) for relapsing multiple sclerosis. 15589058 - Plasma osteopontin levels in multiple sclerosis. 18181768 - Focus groups in swedish psoriatic patients with pruritus. 16628538 - Intensive extracorporeal photochemotherapy in pediatric patients with chronic graft-ver... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Volume: 65 ISSN: 1535-2900 ISO Abbreviation: Am J Health Syst Pharm Publication Date: 2008 Feb |
Date Detail:
|
Created Date: 2008-02-01 Completed Date: 2008-02-21 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9503023 Medline TA: Am J Health Syst Pharm Country: United States |
Other Details:
|
Languages: eng Pagination: 315-21 Citation Subset: IM |
Affiliation:
|
Robert Wood Johnson University Hospital (RWJUH), New Brunswick, NJ, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Inflammatory Agents, Non-Steroidal
/
therapeutic use Antihypertensive Agents / therapeutic use Calcium Channel Blockers / therapeutic use Epoprostenol / analogs & derivatives, therapeutic use Female Gastrointestinal Diseases / drug therapy Humans Immunosuppressive Agents / therapeutic use Joint Diseases / drug therapy Male Muscle Weakness / drug therapy Phosphodiesterase Inhibitors / therapeutic use Pulmonary Fibrosis / drug therapy Quality of Life Raynaud Disease / drug therapy Scleroderma, Systemic / drug therapy*, pathology Sjogren's Syndrome / drug therapy Skin Ulcer / drug therapy |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents, Non-Steroidal; 0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Immunosuppressive Agents; 0/Phosphodiesterase Inhibitors; 35121-78-9/Epoprostenol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Devices for home evaluation of women's health concerns.
Next Document: Use of fibrin glue to treat a persistent pneumothorax with bronchopleural fistula.